Biogen Appoints Adam Keeney as Head of Corporate Development
CAMBRIDGE, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Adam Keeney, Ph.D.,...
COVID-19
Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
Approximately two-thirds of trial patients with Major Depressive Disorder achieving remission following SPL026 treatment sustained remission to six-months Aggregated Remission...
Quipt Home Medical Announces New National Insurance Contract with Top 5 Health Insurer Based on Membership in the United States
Opportunity to Accelerate Long-Term Organic Growth and Expand Patient AccessCINCINNATI, April 04, 2023 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp....
Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, April 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
Comera Life Sciences Announces Expansion of Patent Portfolio Underlying Core Excipient Technology
– Notice of Allowance of U.S. patent application received for expansion of core viscosity reduction claims for excipients in SQore™...
Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine
MINNEAPOLIS, April 03, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics...
Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
Carlsbad, CA, April 03, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic...
A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases
HCW Biologics Published a Pivotal Scientific Paper in Aging Cell Subcutaneous Administration of HCW9218 Systemically Reduces Senescent Cells and Alleviates Senescence-Associated...
NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
NAARDEN, the Netherlands and MIAMI, April 03, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma”...
Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting
NEW YORK and LONDON, April 03, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
ORYZON Announces Positive Results from Planned Interim Analysis of PORTICO, a Phase 2b Adaptive Trial in Borderline Personality Disorder
Based on interim efficacy and safety data, Independent Data Monitoring Committee recommends continuation of the trialMADRID, Spain and BOSTON, April...
Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19
Pomotrelvir did not meet the primary endpoint measured by proportion of participants below the limit of detection for infectious SARS-CoV-2...
Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update
Three patients now dosed in Phase 2 clinical study evaluating ELX-02 for the treatment of Alport syndrome; encouraging initial reduction...
Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs
Expect to complete patient enrollment in the randomized Phase 1/2a SIGNAL-AD Alzheimer’s study in April 2023 with topline data anticipated...
Oncocyte Pricing of $13.86 Million Public Offering of Common Stock
Common Stock Offering Priced At-The-MarketIRVINE, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), a...
Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation
Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) is now approved in the EU for use in all indications of reference...
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active controlSAN DIEGO, April 01, 2023...
Mydecine Reports Financial Results for the Year Ended December 2022
DENVER, March 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"),...
Aridis Provides Corporate Update
LOS GATOS, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical...
StageZero to Issue Q4 2022 Financial Results on Friday March 31
Toronto, Ontario--(Newsfile Corp. - March 30, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company") today announced that...